<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>S-HCL 2 is the prototype antibody of the recently defined CD72 cluster (human Lyb-2) </plain></SENT>
<SENT sid="1" pm="."><plain>Under nonreducing conditions, S-HCL 2 monoclonal antibody (mAb) precipitates a <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> of 80-86 kDa </plain></SENT>
<SENT sid="2" pm="."><plain>Under reducing conditions, a dimer of 43 and 39 kDa, with core proteins of 40 and 36 kDa, is precipitated </plain></SENT>
<SENT sid="3" pm="."><plain>CD72 expression in <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant tissues is different from expression of <z:hpo ids='HP_0000001'>all</z:hpo> other previously described human B-cell antigens </plain></SENT>
<SENT sid="4" pm="."><plain>In peripheral blood and bone marrow, the antigen appears to be present on <z:hpo ids='HP_0000001'>all</z:hpo> B lymphocytes, with the exception of plasma cells </plain></SENT>
<SENT sid="5" pm="."><plain>In tissue, immunohistochemical staining revealed positivity for <z:hpo ids='HP_0000001'>all</z:hpo> known B-cell compartments; however, pulpa macrophages of the spleen and von Kupffer cells exhibited distinct positivity for CD72 also </plain></SENT>
<SENT sid="6" pm="."><plain>Among 83 malignant non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> examined by immunohistochemistry (alkaline phosphatase anti-alkaline phosphatase technique), <z:hpo ids='HP_0000001'>all</z:hpo> 54 B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including precursor B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, germinal center <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemias</z:hpo>, and hairy cell <z:hpo ids='HP_0001909'>leukemias</z:hpo>, were CD72 positive, but no T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were </plain></SENT>
<SENT sid="7" pm="."><plain>Flow cytometry study of more than 80 mainly <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> (52 B-cell <z:hpo ids='HP_0001909'>leukemias</z:hpo>) showed reactivity with S-HCL 2 mAb over the full range of B-cell differentiation </plain></SENT>
<SENT sid="8" pm="."><plain>In particular, very early B cells in cytoplasmic Ig (cIg)-negative, CD19-positive pre-pre-B-cell <z:hpo ids='HP_0001909'>leukemias</z:hpo> and hybrid <z:hpo ids='HP_0001909'>leukemias</z:hpo> (mixed myeloid and B-cell type) were consistently positive for CD72 on the cell surface </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, CD72 may become an important marker for progenitor B-cell <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
</text></document>